Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...
Pfizer has ended the global commercialisation of its haemophilia B (factor IX deficiency) gene therapy Beqvez, citing soft demand for gene therapies among haemophilia patients and physicians.
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a ...
GlobalData on MSN5d
Pfizer shelves haemophilia gene therapy Beqvez amid low demandPfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...
US pharma giant Pfizer has ended all development and commercialization activities relating to fidanacogene elaparvovec, a ...
The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.
According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and ...
Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback